Genomic Valley Biotech Ltd
Incorporated in 2001, Genomic Valley Biotech Ltd is in the business of Horticultural and Agricultural products, and is also adding activities in Human Genomic[1]
- Market Cap ₹ 8.11 Cr.
- Current Price ₹ 26.5
- High / Low ₹ 54.3 / 20.1
- Stock P/E 270
- Book Value ₹ 12.8
- Dividend Yield 0.00 %
- ROCE 1.02 %
- ROE 0.77 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 5.15% over past five years.
- Company has a low return on equity of 3.68% over last 3 years.
- Company has high debtors of 3,136 days.
- Promoter holding has decreased over last 3 years: -21.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.11 | 0.44 | 0.59 | 0.99 | 0.85 | 0.21 | 0.07 | 2.72 | 0.17 | 0.84 | 0.27 | |
| 0.07 | 0.54 | 0.48 | 0.49 | 0.57 | 0.30 | 0.34 | 0.45 | 1.84 | 0.15 | 0.40 | 0.23 | |
| Operating Profit | -0.04 | -0.43 | -0.04 | 0.10 | 0.42 | 0.55 | -0.13 | -0.38 | 0.88 | 0.02 | 0.44 | 0.04 |
| OPM % | -133.33% | -390.91% | -9.09% | 16.95% | 42.42% | 64.71% | -61.90% | -542.86% | 32.35% | 11.76% | 52.38% | 14.81% |
| 0.07 | 0.16 | 0.01 | 0.03 | 0.01 | 0.01 | 0.00 | 0.50 | -0.22 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.05 | 0.04 | 0.08 | 0.19 | 0.18 | 0.19 | 0.08 | 0.01 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.01 | -0.34 | -0.07 | 0.05 | 0.24 | 0.20 | -0.50 | 0.00 | 0.65 | 0.02 | 0.44 | 0.04 |
| Tax % | 0.00% | -2.94% | 0.00% | 40.00% | 0.00% | -40.00% | 12.00% | 0.00% | 0.00% | 20.45% | 25.00% | |
| -0.01 | -0.33 | -0.07 | 0.03 | 0.23 | 0.29 | -0.56 | -0.01 | 0.65 | 0.02 | 0.36 | 0.03 | |
| EPS in Rs | -0.03 | -1.08 | -0.23 | 0.10 | 0.75 | 0.95 | -1.83 | -0.03 | 2.13 | 0.07 | 1.18 | 0.10 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 5% |
| 3 Years: | -54% |
| TTM: | -68% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 15% |
| 3 Years: | -68% |
| TTM: | -92% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 9% |
| 1 Year: | -42% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Reserves | 1.84 | 1.51 | 1.44 | 1.47 | 1.71 | 1.99 | 1.43 | -0.18 | 0.47 | 0.49 | 0.84 | 0.87 |
| 0.75 | 0.75 | 0.75 | 0.75 | 1.48 | 1.48 | 1.55 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.80 | 0.73 | 0.78 | 1.41 | 0.94 | 1.49 | 1.59 | 0.92 | 0.90 | 0.79 | 0.47 | 0.33 | |
| Total Liabilities | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.25 |
| 3.15 | 3.18 | 3.63 | 4.12 | 4.31 | 4.47 | 5.86 | 1.75 | 0.00 | 0.00 | 0.01 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.38 | 0.49 | 0.49 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.55 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| 2.74 | 2.75 | 2.39 | 2.18 | 2.38 | 3.05 | 1.27 | 2.04 | 4.42 | 4.31 | 4.35 | 4.25 | |
| Total Assets | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.25 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.09 | -0.69 | 0.35 | 0.87 | -1.04 | 0.44 | 1.48 | -2.13 | -0.78 | -0.02 | 0.03 | ||
| -0.65 | 0.53 | -0.31 | -0.91 | 0.37 | -0.47 | -1.58 | 3.67 | 1.52 | -0.02 | 0.01 | ||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.73 | 0.00 | 0.07 | -1.55 | -0.70 | 0.00 | 0.00 | ||
| Net Cash Flow | -0.56 | -0.16 | 0.04 | -0.04 | 0.06 | -0.04 | -0.03 | -0.01 | 0.04 | -0.04 | 0.04 | |
| Free Cash Flow | -0.05 | -0.77 | -0.15 | -0.07 | -0.68 | -0.04 | -0.10 | 3.22 | 0.70 | -0.02 | 0.02 | |
| CFO/OP | -225% | 160% | -875% | 870% | -248% | 80% | -1,138% | 561% | -89% | -100% | 27% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 960.30 | 3,136.30 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 486.67 | |||||||
| Days Payable | 17.38 | |||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 1,429.58 | 3,136.30 |
| Working Capital Days | -8,881.67 | -1,659.09 | -514.32 | -804.24 | 55.30 | -176.06 | -1,251.43 | 4,849.29 | 221.42 | 4,530.29 | 916.85 | 3,176.85 |
| ROCE % | 0.35% | -5.84% | -0.57% | 0.57% | 4.17% | 5.96% | -5.10% | -8.54% | 28.48% | 0.57% | 11.84% | 1.02% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue from Operations (Operational Scale Proxy) INR |
|
||||||
| Number of Farmers in Producer Company Network Number |
|||||||
| Hi-Tech Poly Houses (Infrastructure Count) Number |
|||||||
| Naturally Ventilated Poly Houses (Infrastructure Count) Number |
|||||||
| Net Houses (Infrastructure Count) Number |
|||||||
| Genomics Services - Number of NGS Panels/Services Added Number |
|||||||
Extracted by Screener AI
Documents
Announcements
-
To Consider And Approve The Appointment Of Mr. Navjyoti Kumar Jha As Internal Auditor Of The Company For The F.Y. 2026-27
9h - Board approved FY26 audited standalone results and appointed Mr. Navjyoti Kumar Jha as internal auditor for FY27.
-
Results- Financial Results For The Quarter And Year Ended On 31 March 2026
9h - Board approved FY26 audited standalone results and appointed Mr. Navjyoti Kumar Jha as Internal Auditor for FY27.
-
Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of The SEBI (LODR) Regulation 2015 Held On Friday 29Th May 2026.
10h - Board approved FY2026 audited results on 29 May 2026 and appointed internal auditor for FY2026-27.
-
Board Meeting Intimation for Regulation 29 Of SEBI (LODR) Regulations, 2015
18 May - Board meets on 29 May 2026 to approve audited Q4 and FY2026 standalone results; trading window closed from 1 April.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Apr - Regulation 74(5) certificate submitted for quarter ended 31 March 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1][2]
GVBL, with its experience in Next-Generation Sequencing (NGS), oncology, and Artificial Intelligence (AI), provides biotechnology
and healthcare solutions. The company provides personalized therapy options, helping doctors with decision-making support and identifying effective treatments, and aims to transform oncology research and diagnostics.
The company also provides Research Process Outsourcing (RPO) services to global researchers